Marvell Technology, Inc. (MRVL) Stock Forecast
Data as of May 2, 2026Technology · Current price $164.79 (-0.24%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 16, 2026 | Tore Svanberg | Stifel Nicolaus | $140.00 | -15.0% |
| Apr 15, 2026 | Rick Schafer | Oppenheimer | $170.00 | +3.2% |
| Apr 9, 2026 | Tom O'Malley | Barclays | $150.00 | -9.0% |
| Mar 6, 2026 | Hans Mosesmann | Rosenblatt Securities | $140.00 | -15.0% |
| Mar 6, 2026 | Tore Svanberg | Stifel Nicolaus | $120.00 | -27.2% |
| Mar 6, 2026 | Christian Schwab | Craig-Hallum | $164.00 | -0.5% |
| Mar 4, 2026 | Mark Lipacis | Evercore ISI | $133.00 | -19.3% |
| Feb 23, 2026 | Timothy Arcuri | UBS | $120.00 | -27.2% |
| Jan 5, 2026 | Ben Reitzes | Melius Research | $135.00 | -18.1% |
| Dec 3, 2025 | Suji Desilva | Roth Capital | $135.00 | -18.1% |
| Dec 3, 2025 | Mark Lipacis | Evercore ISI | $156.00 | -5.3% |
| Dec 3, 2025 | Tore Svanberg | Stifel Nicolaus | $114.00 | -30.8% |
| Dec 3, 2025 | Tom O'Malley | Barclays | $105.00 | -36.3% |
| Dec 3, 2025 | Joseph Moore | Morgan Stanley | $112.00 | -32.0% |
| Dec 1, 2025 | Joseph Moore | Morgan Stanley | $86.00 | -47.8% |
| Nov 24, 2025 | Frank Lee | HSBC | $85.00 | -48.4% |
| Nov 24, 2025 | Timothy Arcuri | UBS | $110.00 | -33.2% |
| Oct 13, 2025 | Timothy Arcuri | UBS | $105.00 | -36.3% |
| Aug 29, 2025 | Joseph Moore | Morgan Stanley | $76.00 | -53.9% |
| Aug 22, 2025 | Aaron Rakers | Wells Fargo | $95.00 | -42.4% |
Top Analysts Covering MRVL
MRVL vs Sector & Market
| Metric | MRVL | Technology Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.22 | 2.34 | 2.41 |
| Analyst Count | 51 | 13 | 18 |
| Target Upside | -21.4% | +4072.8% | +14.9% |
| P/E Ratio | 53.68 | 27.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-01-31 | $10.01B | $10.87B | $11.33B | 30 |
| 2027-04-30 | $3.10B | $3.26B | $3.35B | 10 |
| 2027-07-31 | $3.36B | $3.53B | $3.62B | 11 |
| 2027-10-31 | $3.67B | $3.85B | $3.95B | 11 |
| 2028-01-31 | $4.03B | $4.24B | $4.35B | 10 |
| 2028-04-30 | $4.20B | $4.41B | $4.53B | 9 |
| 2028-07-31 | $4.47B | $4.69B | $4.82B | 10 |
| 2028-10-31 | $4.75B | $4.99B | $5.12B | 10 |
| 2029-01-31 | $4.99B | $5.24B | $5.38B | 11 |
| 2030-01-31 | $17.99B | $20.91B | $22.03B | 8 |
| 2031-01-31 | $18.80B | $21.86B | $23.03B | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-01-31 | $3.52 | $3.84 | $3.99 | 25 |
| 2027-04-30 | $1.10 | $1.17 | $1.21 | 11 |
| 2027-07-31 | $1.20 | $1.28 | $1.33 | 18 |
| 2027-10-31 | $1.33 | $1.42 | $1.47 | 9 |
| 2028-01-31 | $1.49 | $1.59 | $1.65 | 11 |
| 2028-04-30 | $1.56 | $1.67 | $1.73 | 16 |
| 2028-07-31 | $1.69 | $1.80 | $1.87 | 10 |
| 2028-10-31 | $1.82 | $1.94 | $2.01 | 10 |
| 2029-01-31 | $1.94 | $2.07 | $2.14 | 14 |
| 2030-01-31 | $7.29 | $8.92 | $9.54 | 4 |
| 2031-01-31 | $7.69 | $9.40 | $10.05 | 5 |
Frequently Asked Questions
What is the analyst consensus for MRVL?
The consensus among 51 analysts covering Marvell Technology, Inc. (MRVL) is Buy with an average price target of $120.68.
What is the highest price target for MRVL?
The highest price target for MRVL is $170.00, set by Rick Schafer at Oppenheimer on 2026-04-15.
What is the lowest price target for MRVL?
The lowest price target for MRVL is $50.00, set by Quinn Bolton at Needham on 2022-12-02.
How many analysts cover MRVL?
51 analysts have issued ratings for Marvell Technology, Inc. in the past 12 months.
Is MRVL a buy or sell right now?
Based on 51 analyst ratings, MRVL has a consensus rating of Buy (2.22/5) with a -21.4% upside to the consensus target of $120.68.
What are the earnings estimates for MRVL?
Analysts estimate MRVL will report EPS of $3.84 for the period ending 2027-01-31, with revenue estimated at $10.87B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.